Vimarsana
Biggest News Aggregation in the World

Page 2 - Upfront Payment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Upfront Payment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Upfront Payment Today - Breaking & Trending Today

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License ... - Vimarsana News

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License ...

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License ...

Centre notified mineral auction rules to cap upfront payments - Vimarsana News

Centre notified mineral auction rules to cap upfront payments

In a recent development, the central government has introduced new revisions to the Mineral auction rules. These changes aim to ensure transparency and fair competition in the bidding process. According to the revised rules, the upfront payment for mineral auctions will now be capped at Rs 500 crore.

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY - Vimarsana News

ISOMORPHIC LABS ANNOUNCES STRATEGIC MULTI-TARGET RESEARCH COLLABORATION WITH LILLY

/PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today...

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC - Vimarsana News

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

DAEJEON, South Korea, December 26, 2023--LegoChem Biosciences Announces License Agreement for LCB84, a Trop2 directed ADC with Janssen Biotech, Inc., a Johnson & Johnson company.

Source: yahoo.com
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program - Vimarsana News

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody ...